跳至主要内容
临床试验/JPRN-UMIN000001660
JPRN-UMIN000001660已完成2 期

Phase II trial of neo-adjuvant chemohormonal therapy combining LHRH agonist and estramustine phosphate evaluating PSA failure free survival and safety for locally advanced prostate cancer - Phase II trial of neo-adjuvant chemohormonal therapy combining LHRH agonist and estramustine phosphate evaluating PSA failure free survival and safety for locally advanced prostate cancer

Hirosaki University Graduate School of Medicine0 个研究点目标入组 50 人开始时间: 2009年1月27日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 80years-old(—)
性别
Male

入选标准

  • 未提供

排除标准

  • 1)patients with severe co-morbidity including uncontrollable cardiac, cerebral disease. 2)patients with serious liver dysfunction or serious blood disease. 3)patients with gastroenterial ulcer. 4)Patients who had hypersensitivity to Goserelin or Leuprorelin. 5)patients who fall under the followings: AST, ALT and ALP > 2.5 times upper limit of normal (ULN), Serum creatinine > 1.5 times ULN , Leukocyte count < 3,000/uL, Hemoglobin < 10.0g/dL, Platelet count < 75,000/uL 6)Patients with other cancer requiring treatment

研究者

发起方
Hirosaki University Graduate School of Medicine

相似试验